Who Should NOT Take a GLP-1: Contraindications and Black Box Warnings

Written by Dan Cripe, RN, BSN & Marcia Cripe, RN | Last Updated: September 24, 2026

You start reading the safety information for a GLP-1 medication and suddenly it feels as though half your medical history is on the warning list. Thyroid cancer. Pancreatitis. Gastroparesis. Pregnancy. Gallbladder problems. Kidney disease.

It is easy to come away thinking that having any one of those conditions means you simply cannot take a GLP-1 medication. Sometimes that is true, but often it is not.

The reason is that medication labeling uses several different safety categories that sound similar but do not mean the same thing. A contraindication, a boxed warning, a warning or precaution, and a situation in which treatment is not recommended each carry a different clinical meaning.

For several commonly used GLP-1 and incretin medications, the formal list of absolute contraindications is actually fairly short. Many other conditions require a more individualized decision involving your history, current symptoms, alternative treatments and how much benefit the medication is expected to provide.

Understanding which category your condition actually belongs to is far more useful than simply finding the condition somewhere in a medication insert.

First: What Is an Absolute Contraindication?

A contraindication means the medication should not be used under the circumstances specifically identified in its prescribing information. That is stronger language than a general warning.

A warning tells clinicians and patients about a potentially serious risk that should be considered when deciding whether or how a medication is used. The existence of a warning may mean additional monitoring, a more careful risk-benefit discussion or choosing a different drug in certain patients, but it does not automatically mean the medication is forbidden for everyone with that risk factor.

A boxed warning, sometimes informally called a black box warning, is FDA's most prominent warning format for serious safety risks. Even then, the terms boxed warning and contraindication are not interchangeable.

They can overlap. The thyroid C-cell tumor warning carried by several semaglutide and tirzepatide products is a good example because the labeling contains both a boxed warning about the potential tumor risk and a formal contraindication for people with specific thyroid-cancer histories.

Medullary Thyroid Carcinoma and MEN2 Syndrome Risks

The thyroid warning on medications such as Ozempic, Wegovy, Mounjaro and Zepbound can sound frightening, particularly if you or someone in your family has ever had any kind of thyroid disease.

The warning, however, is much more specific than “anyone with thyroid problems should not take a GLP-1.”

For semaglutide and tirzepatide products carrying this contraindication, treatment should not be used in someone with a personal history of medullary thyroid carcinoma, a family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2.

Those are the histories that matter for this particular contraindication. Ordinary hypothyroidism, Hashimoto disease and most other thyroid diagnoses are not automatically equivalent to MTC or MEN2.

Why is there a thyroid-cancer boxed warning?

In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. The important unresolved question is how relevant those animal findings are to humans.

Current FDA labeling states that it is unknown whether these medications cause thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. The human relevance of the rodent findings has not been established.

That means the boxed warning should not be translated into the much broader statement that “Ozempic causes thyroid cancer.” The evidence does not support that conclusion.

The more accurate interpretation is that C-cell tumors occurred in rodents, the significance for humans remains uncertain, and the medications are specifically contraindicated in people with a personal or family history of MTC or MEN2.

What if your family member had a different thyroid cancer?

This is exactly where knowing the diagnosis matters. Medullary thyroid carcinoma is one particular form of thyroid cancer arising from thyroid C cells, and it is not synonymous with every malignancy that occurs in the thyroid.

A family history of papillary thyroid cancer, for example, is not the same thing as a family history of MTC. Likewise, having hypothyroidism or taking levothyroxine does not mean you have the thyroid-cancer contraindication listed for semaglutide or tirzepatide.

If all you know is that a close relative once had “thyroid cancer,” finding out which type can be clinically important. The exact pathology can determine whether the history falls within the formal contraindication.

This is a good example of why broad internet advice can create unnecessary fear. One word — thyroid — is not enough to determine whether the medication is appropriate.

Should everyone get thyroid ultrasounds or calcitonin testing first?

Current prescribing information does not recommend routine thyroid ultrasound or routine serum calcitonin testing for every person simply because they are starting one of these medications.

The labeling describes routine calcitonin measurement or thyroid ultrasound specifically for early detection of MTC as being of uncertain value. Screening large numbers of people without another reason for testing can also create abnormal results that require further evaluation without necessarily improving outcomes.

That does not mean concerning thyroid findings should be ignored. An existing thyroid nodule, substantially elevated calcitonin, a neck mass, persistent hoarseness, difficulty swallowing or another suspicious finding deserves appropriate medical evaluation.

The distinction is that the boxed warning does not translate into a requirement that every person beginning GLP-1 treatment first undergo thyroid imaging.

Serious Hypersensitivity Is Also a Contraindication

Serious allergic reactions receive far less attention than the thyroid warning, but they belong on the true contraindication list.

Semaglutide and tirzepatide products are contraindicated in people with a known serious hypersensitivity to the active medication or relevant product ingredients. Serious reactions including anaphylaxis and angioedema have been reported.

This should not be confused with common medication side effects. Nausea after a GLP-1 dose may be unpleasant, but it is not the same biological event as a potentially life-threatening allergic reaction involving airway swelling, difficulty breathing or cardiovascular instability.

If you have previously had a serious hypersensitivity reaction to the medication or one of its ingredients, that history needs to be addressed explicitly before there is any further exposure.

Pancreatic Inflammation and Previous Flare-Ups: Can You Take a GLP-1 With a History of Pancreatitis?

A history of pancreatitis is one of the areas where online advice often becomes more absolute than the medication labeling itself.

Previous pancreatitis is not universally listed as a formal contraindication to GLP-1 receptor agonist treatment. Acute pancreatitis is, however, a recognized serious safety concern, and cases — including severe cases — have been reported in people receiving incretin medications.

That means a previous episode should not simply be ignored. The decision may depend on what caused the pancreatitis, whether that cause remains present, whether episodes have recurred, what alternative obesity or diabetes treatments are available and how much benefit GLP-1 treatment is expected to provide.

For someone with this history, the right question is usually not simply “Have you ever had pancreatitis?” The details surrounding that pancreatitis matter.

Previous pancreatitis is not one single clinical situation

A person who had gallstone pancreatitis years ago, had the underlying gallbladder problem treated and has never had another episode is clinically different from someone with recurrent pancreatitis from an ongoing disorder.

A third person may have developed pancreatitis during severe hypertriglyceridemia that remains poorly controlled. All three histories contain the same word, but the factors affecting future risk are not necessarily the same.

That is why the blanket statement “You had pancreatitis once, so you can never use a GLP-1” is too broad. Previous pancreatitis deserves individualized assessment rather than being automatically converted into a class-wide lifetime prohibition.

The same principle works in the opposite direction. Because previous pancreatitis is not always a formal contraindication, it should not be dismissed as irrelevant either.

What happens if pancreatitis is suspected while you're taking one?

This situation is much more straightforward. Persistent severe abdominal pain, particularly pain that may radiate toward the back and may occur with or without vomiting, needs prompt medical evaluation.

Current product labeling directs clinicians to discontinue treatment when pancreatitis is suspected and manage the suspected pancreatitis appropriately.

This is not a symptom pattern to watch at home for several days while continuing injections to see whether it goes away. Severe persistent abdominal pain deserves assessment before another dose is treated as routine.

Pregnancy: GLP-1 Use and Fetal Safety

Weight-loss treatment is not recommended during pregnancy because intentional weight reduction provides no benefit during pregnancy and can introduce unnecessary risk.

For medications approved for chronic weight management, pregnancy therefore changes the treatment decision immediately. Current labeling for products such as Wegovy and Zepbound directs patients to discontinue treatment when pregnancy is recognized.

Animal reproductive studies have also raised concerns about fetal risk with GLP-1 and incretin medications, while available human pregnancy data remain limited. That uncertainty is another reason these medications are not treated as routine obesity therapy during pregnancy.

If you discover that you are pregnant while taking one, contact the clinician prescribing it rather than simply continuing treatment until your next scheduled appointment.

Planning pregnancy matters too

Some GLP-1 medications remain in the body for weeks after the final dose, so pregnancy planning sometimes requires stopping treatment well before you begin trying to conceive.

Semaglutide is the clearest example. Because of its long washout period, current Ozempic labeling recommends discontinuing semaglutide at least two months before a planned pregnancy.

That two-month recommendation should not automatically be applied to every GLP-1 medication. Tirzepatide, liraglutide, dulaglutide and future incretin medications have different pharmacokinetics and product-specific labeling.

If you are planning pregnancy, the relevant timeline is therefore the one attached to the specific medication you use, not a generic “GLP-1 washout” number.

Tirzepatide and Oral Contraceptives

Tirzepatide creates another reproductive issue that is separate from pregnancy exposure itself.

Because tirzepatide delays gastric emptying, it can affect absorption of oral hormonal contraceptives. Current labeling therefore advises people who rely on oral hormonal contraception to switch to a non-oral method or add a barrier method for four weeks after starting tirzepatide and for four weeks after every dose escalation.

That recommendation can matter repeatedly during the early months of treatment because tirzepatide is commonly increased through several dose levels.

Non-oral contraceptive methods do not depend on gastrointestinal absorption in the same way, so this should not be generalized into the statement that tirzepatide makes every form of contraception less effective.

If pregnancy prevention matters to you, your contraceptive method should be part of the treatment conversation when tirzepatide is first prescribed rather than something you discover after a dose increase.

Breastfeeding Is More Nuanced Than Pregnancy

Pregnancy and breastfeeding are frequently grouped together in medication discussions, but the available evidence and recommendations are not identical.

Lactation information is product specific and evolving. For some GLP-1 medications, human milk data remain limited or absent, while newer lactation studies have begun providing information for certain drugs and formulations.

The decision can also depend on why the medication is being used, the age and health of the infant, the mother's clinical need for treatment and what reasonable alternatives are available.

That makes both extreme statements — “all GLP-1s are absolutely contraindicated during breastfeeding” and “they are safe because very little gets into breast milk” — too broad.

If you are breastfeeding or planning to breastfeed, use the current lactation section of the prescribing information for the exact product you take and discuss the risk-benefit decision with your clinician.

Evidence involving one formulation should not automatically be applied to injectable semaglutide, oral semaglutide, tirzepatide, liraglutide or every other drug in the class.

Pre-Existing Dysmotility and Digestive Tract Obstruction

GLP-1 medications alter gastrointestinal motility as part of their normal pharmacology. They can delay gastric emptying and commonly cause nausea, vomiting, constipation, abdominal discomfort and early fullness, particularly during treatment initiation and dose escalation.

For someone who already has significant gastrointestinal dysmotility, that deserves additional attention. A medication that intentionally slows part of gastrointestinal transit can interact very differently with an already impaired digestive system than it does with normal motility.

This does not mean every person with constipation, reflux or occasional fullness has a serious motility disorder. The severity and underlying diagnosis matter.

When meaningful dysmotility is already present before treatment, it should be discussed before assuming the usual GLP-1 gastrointestinal effects will be tolerable.

Severe gastroparesis

For several current incretin products, including Zepbound, severe gastroparesis is described as a situation in which treatment is not recommended.

That wording is technically different from a formal contraindication, but it is still clinically important. If your stomach already has major difficulty moving food forward, adding a medication known to delay gastric emptying can worsen symptoms and complicate nutritional and gastrointestinal management.

Someone with diagnosed severe gastroparesis should therefore not approach GLP-1 treatment as though the only issue is whether they might experience a little additional nausea.

The condition should be discussed before treatment begins so the prescribing clinician can evaluate whether another medication is more appropriate.

What if you're simply constipated?

Constipation is not synonymous with gastroparesis, and feeling full quickly after starting a GLP-1 does not automatically mean you have developed a severe motility disorder.

GLP-1 medications commonly change gastrointestinal function. Mild or moderate constipation and increased satiation can occur as part of ordinary treatment.

The important distinction is whether symptoms are escalating or suggesting something more serious. Persistent vomiting, inability to tolerate fluids, severe or increasing abdominal pain, substantial abdominal distension or symptoms concerning for obstruction require medical evaluation.

Not every digestive side effect is a contraindication. Severe or progressive symptoms, however, should not be dismissed simply because gastrointestinal effects are common with the drug class.

Gallbladder Disease Is Another Warning — Not Automatically a Contraindication

GLP-1 and incretin medications are associated with gallbladder events including gallstones and cholecystitis. Rapid and substantial weight loss itself can also increase the risk of gallstone formation.

A history of gallbladder disease does not automatically equal an absolute GLP-1 contraindication. The current clinical circumstances matter much more than the fact that the gallbladder appears somewhere in your past medical history.

Someone who had their gallbladder removed years ago and is currently asymptomatic is in a very different situation from someone experiencing active symptoms concerning for acute cholecystitis.

If you develop substantial upper abdominal pain, fever, jaundice or other symptoms concerning for gallbladder disease while using a GLP-1 medication, seek medical evaluation rather than assuming the symptoms are ordinary medication-related stomach upset.

Kidney Disease Usually Isn't an Absolute Contraindication Either

Chronic kidney disease is another condition that is sometimes mistakenly treated as though it automatically prevents GLP-1 use.

For many GLP-1 medications, that is not true. Some products have substantial renal-outcome evidence, and semaglutide now has an FDA-approved indication involving reduction of certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.

The kidney concern often appears indirectly through gastrointestinal adverse effects. Severe nausea, vomiting or diarrhea can lead to dehydration, and significant volume depletion can contribute to acute kidney injury.

If you already have impaired kidney function, the margin for additional dehydration may be smaller. Persistent gastrointestinal losses therefore deserve particular attention even when the medication itself is not formally contraindicated because of chronic kidney disease.

This is another example of why underlying condition + treatment effect can matter more than a simple yes-or-no interaction.

Diabetic Retinopathy Requires Another Kind of Caution

Semaglutide labeling includes a warning regarding diabetic retinopathy complications, but that warning should not be interpreted as meaning semaglutide universally damages the eyes.

Rapid improvement in glucose control has long been associated with temporary worsening of diabetic retinopathy in some people. A powerful glucose-lowering treatment can therefore change eye risk even when the medication is improving diabetes overall.

If you have diabetes and pre-existing retinopathy, your clinician may recommend appropriate ophthalmologic monitoring as glycemic control improves.

A history of diabetic retinopathy does not automatically mean semaglutide cannot be used. It means the existing eye disease becomes part of the monitoring plan.

This is another clear example of why warning and contraindication should not be treated as interchangeable words.

Surgery and Anesthesia: Tell the Team You're Taking a GLP-1

GLP-1 medications' effects on gastric emptying have created an important perioperative safety issue because residual stomach contents can increase the risk of pulmonary aspiration during general anesthesia or deep sedation.

Reports of aspiration have occurred in people taking GLP-1 receptor agonists despite reported adherence to ordinary preoperative fasting instructions. Current prescribing information therefore tells patients to inform healthcare professionals about planned procedures.

That does not mean every person should independently stop their medication for a fixed number of days before surgery. Periprocedural recommendations have evolved as evidence has developed and now depend on factors including the medication, treatment phase, gastrointestinal symptoms, procedure and individual aspiration risk.

Tell your surgeon, anesthesia team and prescribing clinician what medication you take and when you last took it. Let the procedural team determine whether treatment should continue, be held or be managed with another strategy.

The Difference Between “Do Not Take,” “Not Recommended,” and “Use With Caution”

These categories are easier to understand when they are placed side by side because they answer different clinical questions.

The terminology is not bureaucratic trivia. It prevents two very different safety errors: using a medication when there is a genuine contraindication and unnecessarily ruling out an effective treatment because a precaution was mistaken for an absolute prohibition.

The sections below make those distinctions more explicit.

A true contraindication

For commonly used semaglutide and tirzepatide products, major examples include a personal or family history of medullary thyroid carcinoma, MEN2, and known serious hypersensitivity to the medication or relevant ingredients.

These are explicit label-level reasons the medication should not be used. They are fundamentally different from a common side effect or a condition that merely requires closer monitoring.

If one of these applies to you, the question is not how to “work around” the contraindication on your own. Another treatment strategy should be discussed with your clinician.

A situation where treatment may not be recommended

Severe gastroparesis is an important example. For several modern incretin products, the labeling uses wording such as not recommended rather than placing the condition in the formal contraindications section.

From a clinical standpoint, that distinction should not make the concern seem trivial. A medication that further delays gastric emptying may be poorly suited to someone who already has severe gastric motility impairment.

The regulatory wording is different, but the practical consequence may still be choosing another treatment.

A warning or precaution

Warnings and precautions identify serious issues that need attention without automatically ruling out treatment for everyone with a related history.

Examples include acute pancreatitis, gallbladder disease, volume depletion and acute kidney injury, diabetic retinopathy complications for applicable semaglutide products, hypoglycemia when combined with insulin or insulin secretagogues, and aspiration risk around anesthesia or deep sedation.

The response may involve monitoring, modifying another medication, treating an underlying risk factor or choosing a different GLP-1 product in selected circumstances.

What it does not mean is that every person who has ever had one of these conditions is automatically prohibited from using the entire medication class.

A special population requiring its own risk-benefit decision

Pregnancy and lactation illustrate why some situations do not fit neatly into a simple contraindication checklist.

Weight-loss treatment should be discontinued during pregnancy, while pregnancy planning may require a medication-specific washout period. Breastfeeding decisions are more product specific because lactation data vary across drugs and formulations.

The broader lesson is that special populations require current, product-specific information rather than assumptions applied across an entire class.

Using the correct category produces better decisions than simply labeling every complicated situation a contraindication.

When You Should Get Medical Help

Some symptoms should not wait until your next routine follow-up. Seek prompt medical evaluation for:

• Severe, persistent abdominal pain, particularly if it radiates toward your back.
• Repeated vomiting or inability to keep fluids down.
• Signs of a severe allergic reaction, including facial or throat swelling or difficulty breathing.
• Severe abdominal distension or symptoms concerning for bowel obstruction.
• Significant upper abdominal pain with fever or jaundice.
• A new neck mass, persistent hoarseness, difficulty swallowing or unexplained breathing difficulty.

If you discover that you are pregnant while taking a GLP-1 or incretin medication, contact the clinician prescribing it promptly for medication-specific instructions.

These symptoms are different from routine nausea, mild constipation or expected appetite changes. The fact that gastrointestinal side effects are common should not become a reason to normalize severe or progressive symptoms.

What to Do Before Starting a GLP-1

Do not simply tell your prescriber that you “don't have any contraindications.” Give them the history they need to determine that accurately.

Make sure they know about:

• Any personal or family history of medullary thyroid carcinoma.
• MEN2.
• Previous serious medication allergies or reactions.
• Any history of pancreatitis.
• Diagnosed gastroparesis or other significant gastrointestinal motility disorders.
• Gallbladder disease.
• Kidney disease.
• Diabetic retinopathy.
• Pregnancy, breastfeeding or plans to conceive.
• Your contraceptive method if tirzepatide is being considered.
• Any upcoming procedure involving anesthesia or deep sedation.

That history does not exist to create an enormous list of reasons you cannot receive treatment. It helps separate the relatively small number of true do-not-use situations from the much larger group of medical issues that simply require the right level of caution.

When every warning is called a contraindication, the word loses its usefulness. When you're deciding whether a GLP-1 medication is appropriate for your body, that distinction matters.

Sources

1. Novo Nordisk. Ozempic (semaglutide) U.S. Prescribing Information.
   https://www.novo-pi.com/ozempic.pdf
2. Novo Nordisk. Wegovy (semaglutide) U.S. Prescribing Information.
   https://www.novo-pi.com/wegovy.pdf
3. Eli Lilly and Company. Mounjaro (tirzepatide) U.S. Prescribing Information.
   https://pi.lilly.com/us/mounjaro-uspi.pdf
4. Eli Lilly and Company. Zepbound (tirzepatide) U.S. Prescribing Information.
   https://pi.lilly.com/us/zepbound-uspi.pdf
5. Novo Nordisk. Saxenda (liraglutide) U.S. Prescribing Information.
   https://www.novo-pi.com/saxenda.pdf
6. Eli Lilly and Company. Trulicity (dulaglutide) U.S. Prescribing Information.
   https://pi.lilly.com/us/trulicity-uspi.pdf
7. U.S. Food and Drug Administration. Pregnancy and Lactation Labeling Resources.
   https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-resources